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ABSTRACT
Objective: The purpose of this study was to assess the effectiveness and tolerability of atom-
oxetine during acute treatment of attention-deficit/hyperactivity disorder (ADHD) in 5 and 6
year olds.
Method: Twenty two children (male n 5 19, 86%) with ADHD were treated with atomoxe-
tine for 8 weeks in a three-site, open-label pilot study. Dosing was flexible, with titration to
a maximum of 1.8 mg/kg per day. Parent education on behavior management was provided
as part of each pharmacotherapy visit.
Results: Subjects demonstrated a mean decrease of 20.68 points (SD 5 12.80, p , 0.001)) on
the ADHD Rating Scale-IV (ADHD-IV-RS) total score, 10.18 (SD 5 7.48, p , 0.001) on the inat-
tentive subscale and 10.50 (SD 5 7.04, p , 0.001) on the hyperactive/impulsive subscale. Clin-
ical Global Impression–Severity (CGI-S) was improved in 82% of the children (95% CI, 66–98%)
and Children’s Global Assessment (CGAS) scores improved 18.91 points on average (SD 5
12.20, p , 0.001). The mean final dose of atomoxetine was 1.25 mg/kg per day (SD 5 0.35 mg/kg
per day). Mood lability was the most commonly reported adverse event (n 5 12, 54.5%). Eleven
subjects (50%) reported decreased appetite and a mean weight loss of 1.04 kg (SD 5 0.80 kg)
(p , 0.001) was observed for the group. Vital sign changes were mild and not clinically sig-
nificant. There were no discontinuations due to adverse events or lack of efficacy.
Conclusion: Atomoxetine was generally effective for reducing core ADHD symptoms in the
5 and 6 year olds in this open-label study.
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INTRODUCTION
APPROXIMATELY 3–7% of school-aged chil-dren are affected by attention-deficit/hy-
peractivity disorder (ADHD), yet limited data
are available regarding treatment of youngsters
early in its course (American Psychiatric Asso-
ciation 2000). Symptoms of this neurodevelop-
1University of Nebraska Medical Center, Omaha, Nebraska.
2Duke University Medical Center, Durham, North Carolina.
3Columbia University/New York State Psychiatric Institute, New York, New York.
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mental disorder are often identifiable at an
early age, with epidemiological data indicating
that approximately 2% of children ages 3–5
years meet diagnostic criteria for ADHD (Lav-
igne et al. 1996). When compared to their un-
affected counterparts, preschool children with
ADHD are at significant risk for behavioral, so-
cial, familial, and school difficulties (DuPaul et
al. 2001). In a study of 94 3- to 5-year-old chil-
dren, DuPaul and colleagues showed that not
only were children with ADHD demonstrating
more behavioral problems than children with-
out ADHD, but the difference in behavioral rat-
ings between the groups was significant,
greater than 2 SD. Additionally, skill deficits in
basic math concepts, prereading, and fine mo-
tor abilities are more likely seen in children en-
tering school with ADHD than in those with-
out the disorder (Lahey et al. 1998; Mariani and
Barkley 1997; Shelton et al. 1998). When these
deficits are combined with the potential for sig-
nificant social and behavioral difficulties, im-
pairment may result and ultimately persist if
appropriate interventions are not initiated. In
addition, ADHD symptoms can tax parent and
caregiver resources, resulting in a strained
home environment for these young children. A
study by Escobar and colleagues demonstrated
that parents of children with ADHD perceived
the level of interference in daily life to be
greater than that reported by parents of normal
controls, as well as parents of asthmatic chil-
dren (Escobar et al. 2005).
Despite evidence suggesting that the initial
symptoms of ADHD often present by 3 years
of age, systematic study of the use of medica-
tions in 3- to 6-year-old children with ADHD
has been quite limited (Food and Drug Ad-
ministration 1997; Food and Drug Administra-
tion 1997; National Institutes of Health 1998).
The need for additional research on the safety
and efficacy of psychotropic medication use in
preschoolers has been emphasized, especially
in light of the rates of prescriptions for this age
group (Greenhill 1998). Zito and colleagues
found a three-fold increase in the use of psy-
chotropic agents in 2- to 5-year-old children
from 1991 to 1995 (Zito et al. 2000). Zuvekas et
al. analyzed data from the Medical Expendi-
ture Panel Survey (MEPS) and found that an
estimated 0.3% of children under age 6 were
treated with psychostimulants from 1997 to
2002 (Zuvekas et al. 2006). While stimulant use
in children under age 18 increased from 2.7%
to 2.9% during those 5 years, the rate of use in
the preschool age group remained stable, indi-
cating that prescription of ADHD medications
in young children may be leveling off in this
group. Another database, however, indicated
that use of stimulants in this population may
be increasing, as a 2004 report by Medco Health
Solutions showed a 49% increase in the num-
ber of stimulant prescriptions written for
preschoolers from 2000 to 2003 (Greenhill et al.
2006).
Unfortunately, until recently, only 10 of over
160 controlled trials of psychostimulants for
school-aged children included preschoolers
ages 4–6, and all 10 assessed the use of
methylphenidate (MPH) (Conners 1975;
Schleifer et al. 1975; Cohen et al. 1981; Barkley
et al. 1984; Barkley 1988; Mayes et al. 1994;
Musten et al. 1997; Firestone et al. 1998; Han-
den et al. 1999; Chacko et al. 2005). Even in
these few trials, not all of the samples were
made up entirely of young children. By merg-
ing samples of younger and older children, lim-
itations present, in that the studies are not nec-
essarily specifically designed to evaluate and
monitor symptoms in younger children. Scales
may not be normed for both groups, appropri-
ateness of diagnostic assessments may vary,
and the studies may be underpowered solely
to examine the younger children in the sample.
The recently completed Preschool ADHD
Treatment Study (PATS), a multisite trial of 303
preschoolers with ADHD added significantly
to this literature base in that it was designed
solely for young children and adequately pow-
ered, but again this study examined MPH
(Greenhill et al. 2006).
Although stimulants have been shown to be
safe and effective in the treatment of ADHD in
children, adolescents, and adults, a range of
factors have led parents and clinicians to seek
alternative medication treatments, especially
for younger children. As such, there has been
considerable interest in developing additional
treatments, including nonstimulant options,
for ADHD.
Although information on the use of stimu-
lants in preschoolers is limited, data on the use
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of nonstimulants in young children with
ADHD is virtually nonexistent. A review of the
PharMetrics database shows that a significant
number of prescriptions of atomoxetine are
written for children under 5 years of age, de-
spite the lack of data on its use in children
younger than 6 years old (Van Brunt et al.
2005). Thus, the management of preschool
ADHD with nonstimulant pharmacotherapy
currently requires clinicians to extrapolate
from the data available on use of these med-
ications in older children and adolescents to
guide their clinical practice.
Atomoxetine is a nonstimulant medication
that received Food and Drug Administration
(FDA) approval for the treatment of ADHD in
children 6 years and older, adolescents, and
adults in November, 2002. Atomoxetine acts by
selectively blocking the presynaptic norepi-
nephrine transporter, increasing noradrenergic
tone. It is highly specific, with minimal affinity
for other receptors or other neuronal trans-
porters (Spencer et al. 1998). To date, approxi-
mately 5,500 children and adolescents have
been treated with atomoxetine in clinical trials.
As the only nonstimulant medication FDA
approved for the treatment of ADHD, and one
clinically used off-label in the treatment of
ADHD in young children, atomoxetine was se-
lected as the medication to be examined in this
clinical trial. The goal of this pilot study was to
evaluate systematically the effectiveness and
tolerability of atomoxetine for the treatment of
ADHD in children 5 and 6 years of age, and to
collect pilot data for a larger double-blind,
placebo-controlled trial.
METHODS
This study was a 22-subject feasibility trial
that included children aged 5 and 6 years old
who met Diagnostic and Statistical Manual of
Mental Disorders, 4th edition, Text Revision
(DSM-IV-TR) (American Psychiatric Associa-
tion 2000) criteria for ADHD, any subtype, as
confirmed by the Diagnostic Interview Sched-
ule for Children-IV (DISC-IV) (Shaffer et al.
2000) and clinical interview. Symptom severity
as measured by the ADHD Rating Scale-IV, by
parent interview (ADHD-IV-RS) (DuPaul et al.
1998) at entry was required to be at least 1.5 SD
above age and gender norms. Impairment as
measured by the Clinical Global Impres-
sion–ADHD–Severity scale (CGI-S) (Guy 1976)
had to be at least 4 (moderate severity), with a
Children’s Global Assessment Scale (CGAS)
#55. Subjects were required to have estimated
IQ’s of $70. Patients who previously failed a
trial of atomoxetine or who were already being
effectively treated with atomoxetine were not
included in the study. Diagnoses of an adjust-
ment disorder, autism, psychosis, bipolar dis-
order, significant suicidality, or any other psy-
chiatric disorder requiring treatment with
additional medications were exclusionary, as
was the presence of current or previous clini-
cally significant hepatic disease, or any signif-
icant medical condition that would interfere
with the study medication. Each case was dis-
cussed on a conference call, which included
study personnel from each of the three sites,
and a consensus decision regarding appropri-
ateness for enrollment was required prior to
initiation of study treatment. Several of these
inclusion criteria were chosen to be consistent
with the PATS, and also to provide a relatively
conservative approach to inclusion.
The study was conducted at three sites in the
United States: University of Nebraska Medical
Center in Omaha, NE; Duke University Med-
ical Center in Durham, NC; and Columbia Uni-
versity/New York State Psychiatric Institute in
New York, NY. Prior to entering the study,
there was a review of the consent document,
oral description and discussion of the study,
and written informed consent was obtained
from a parent or guardian for each patient. The
study was reviewed and approved by each
site’s ethical review board and was conducted
in accordance with the ethical standards of the
1975 Declarations of Helsinki as revised in 2000
(World Medical Association 2000).
Measures
An initial assessment using the DISC-IV was
completed interview style with the parent/
guardian, followed by a clinical diagnostic as-
sessment with a psychiatrist, psychologist or
advanced practice registered nurse (APRN)
trained and experienced in the assessment and
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treatment of pediatric mental health disorders.
The clinical diagnostic assessment confirmed
or refuted any co-morbid psychiatric diagnoses
reported on the DISC-IV, and also evaluated
the child for co-morbid diagnoses potentially
missed by the computerized interview. The
DISC-IV was used in PATS in a similar man-
ner, despite lacking norms for children under
the age of 6. The primary efficacy measure for
the study was the ADHD-IV-RS, completed by
investigator interview with the parent at study
entry and at all subsequent visits, along with
the CGI-S and CGAS. The Clinical Global Im-
pression–Improvement (CGI-I) was completed
at each visit following baseline. All of these
measures were completed by the pharma-
cotherapist, a physician, or APRN with exten-
sive experience using pharmacotherapy to treat
young children with ADHD. An effort was
made to have the same pharmacotherapist fol-
low each child throughout his or her study par-
ticipation.
Additional measures completed at the study
screening visit included the Multidimensional
Anxiety Scale for Children (MASC) (March et al.
1997), Children’s Depression Inventory (CDI)
(Kovacs 2001), and Childhood Autism Rating
Scale (CARS) (Garfin et al. 1988). The Peabody
Picture Vocabulary Test (PPVT-IIIA) (Dunn and
Dunn 1997), an assessment of receptive lan-
guage abilities, was completed at the initial eval-
uation visit as a proxy for intelligence quotient
(IQ), given the correlation of receptive language
with general cognitive ability. Scales completed
by the parent included the Conners’ Parent Rat-
ing Scale-Revised (L) (CPRS) (Conners et al.
1998a) and Parent Stress Index (PSI) (Abidin
1995). The child’s teacher, or structured day-care
provider in the case of those children not yet en-
rolled in school, completed the Conners’
Teacher Rating Scale–Revised (L) (CTRS) (Con-
ners et al. 1998b) and the teacher version of the
ADHD-IV rating scale. The teacher scales, as
well as MASC, CDI, CPRS, and PSI, were re-
peated at visit 5 and again at study completion
(visit 8 or early discontinuation).
Safety analyses
Baseline height, weight, and vital signs, in-
cluding heart rate and blood pressure, were ob-
tained at study entry. Weight and vital signs
were assessed at each subsequent visit, and
height was measured again at the final study
visit. Laboratory tests [complete blood count
(CBC), liver function tests (LFT’s), electrolytes,
blood urea nitrogen (BUN), creatinine, and
lead level], an electrocardiogram (EKG), and
physical examination were performed at the
screening visit. Hematology, chemistry, EKG,
and physical examination were repeated at the
final study visit. Preexisting conditions were
reviewed at the screening visit and monitored
for changes during study participation. Ad-
verse events and concomitant medications
were assessed by the physician or APRN pre-
scribing and monitoring the study medication
at each visit via open-ended discussion with
the parent/guardian. The prescribing clinician
evaluated the relatedness to the study drug for
each event. Clinically significant laboratory
and EKG results were documented as adverse
events.
Study design
Once approved to enter the trial, study treat-
ment with open-label atomoxetine was initi-
ated. Atomoxetine was dosed by weight and
increased at the discretion of the investigator
on the basis of tolerability and response. The
initial dose of atomoxetine was 0.5 mg/kg per
day, with titration to a maximum of 0.8 mg/kg
per day at week 1, 1.2 mg/kg per day at week
2, 1.4 mg/kg per day at week 3, and 1.8 mg/kg
per day at week 5. Patients could be dosed once
or twice daily. The parent/guardian also par-
ticipated in an 8-week parent education proto-
col administered by the pharmacotherapist
during the course of each pharmacotherapy
visit to be consistent with practice guidelines
recommending nonpharmacological interven-
tions for this age group. Approximately 10–15
minutes of each pharmacotherapy visit were
spent in parent education using an eight-ses-
sion protocol adapted in part from McMahon
and Forehand’s “Helping the Noncompliant
Child: Family-Based Treatment for Opposi-
tional Behavior” (McMahon and Forehand
2003). Education on ADHD and identification
of target behaviors for improvement comprised
the first session, with two subsequent sessions
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on rewarding positive and ignoring negative
behavior, and giving clear instructions. Op-
tional sessions at visits 5–7 included effective
utilization of time out, challenges to time out,
standing rules, and implementation of a token-
reinforcement program or daily report card for
home and school use. The optional modules
were selected at the discretion of the pharma-
cotherapist to tailor the parent education to the
needs of the child.
Data analysis
Descriptive statistics were used to describe
the baseline patient characteristics and out-
come variables. The Wilcoxon signed-rank test
was used to determine whether the median
change in the outcome variables was statisti-
cally significant (tested the null hypothesis that
the median change over the treatment period
was 0). Data analyses were conducted on the
22 patients who took study drug.
RESULTS
A total of 30 subjects completed the screen-
ing visit, with 22 of these meeting all entry cri-
teria and initiating study treatment at visit two.
Six of the 8 subjects who did not proceed to the
treatment phase of the study were excluded
due to a failure to meet criteria for a diagnosis
of ADHD. One subject withdrew consent prior
to beginning atomoxetine and 1 subject refused
the required blood draw. Two subjects (6.7%)
withdrew from the study after completion of
visit 3 due to inability to consistently swallow
the capsules containing study medication.
Twenty of the 22 patients who began treatment
(90.9%) completed the study.
Nineteen males and 3 females met all inclu-
sion and no exclusion criteria and were eligi-
ble to begin study treatment (Table 1). These
subjects had a mean age at baseline 6.06 years
(SD 0.58 years). The majority of subjects met
criteria for the combined subtype of ADHD
(n 5 18, 82%), with the remaining 4 subjects
meeting criteria for the hyperactive/impulsive
subtype. The mean baseline ADHD-IV-RS to-
tal score was 38.23 (SD 8.05), with a mean inat-
tentive subscale of 18.23 (SD 4.21) and mean
hyperactive impulsive subscale of 20.0 (SD 5
5.43). Nearly three fourths of subjects (n 5 16,
73%) had a baseline CGI-S of 5 (markedly ill),
with a mean baseline CGAS for the group of
53.23 (SD 3.85). There were no significant dif-
ferences in ADHD severity between the 5 year
olds and the 6 year olds at baseline, as mea-
sured by the ADHD-IV-RS total score, sub-
scales, CGI-S, or CGAS. Twelve subjects (55%)
were identified as having co-morbid opposi-
tional defiant disorder, 5 (23%) had enuresis,
and 2 (9%) met criteria for simple phobia. The
mean CARS score for the group was 17.07
(SD 5 1.83), with a range of 15–21, which is in
the nonautistic range. The mean standard score
for the PPVT-IIIA was 106.50 (SD 5 13.07). All
subjects who participated in the treatment por-
tion of the study were treatment naïve.
The final total daily dose of atomoxetine
ranged from 10 to 45 mg/day, with a mean to-
tal daily dose of 30.23 mg/day (SD 5 9.70). By
weight, the final mean total daily dose was 1.25
mg/kg per day, SD 5 0.35, with a range of
0.47–1.88 mg/kg per day. The atomoxetine was
given in either a single morning dose (n 5 20)
or in divided doses given morning and after-
noon (n 5 2). Though slightly higher than the
final mean doses of older children in prior ato-
moxetine studies, it was below the FDA-ap-
proved maximum dose of 1.4 mg/kg per day.
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TABLE 1. DEMOGRAPHICSa
Characteristic Count
Age at visit 1 (years)
Mean (SD) 6.06 (0.58)
5 year old 10 (45%)













Simple phobia 2 (9%)
Phonological disorder 1 (5%)
ADHD 5 Attention-deficit/hyperactivity disorder;
ODD 5 oppositional defiant disorder; SD 5 standard de-
viation
aN 5 22.
The subjects demonstrated a mean decrease
in the ADHD-IV-RS total score of 20.68 points
(SD 5 12.80, p , 0.001), with mean improve-
ments in the inattentive subscale of 10.18 points
(SD 5 7.48, p , 0.001) and 10.50 points in the
hyperactive/impulsive subscale (SD 5 7.04,
p , 0.001) (Fig. 1). At the end point, CGI-S was
improved in 82% (95% CI, 66–98%) (Table 2)
and mean improvement in CGAS score was
18.91 points (SD 5 12.20, p , 0.001). Clinical
improvement was reflected by the final CGI-I
ratings, where 86% showed at least some im-
provement (95% CI, 72–100%). Sixteen of the 22
subjects who started study drug (72.7%)
achieved the generally accepted criteria for re-
sponse, a CGI-I score of 1 (very much im-
proved) or 2 (much improved) by study end
point (Fig. 2). The mean final total daily dose
of atomoxetine (1.25 mg/kg per day, SD 5
0.35) was below the FDA-approved maximum
dose of 1.4 mg/kg per day, but near the ap-
proved target dose of 1.2 mg/kg per day.
Table 3 compares changes in outcome mea-
sures based upon age. Descriptively, the 5-
year-old group appears to demonstrate greater
improvement over time compared with the 6-
year-old group, although with limited power,
only the ADHD-IV inattentive subscale was
statistically significant.
The most frequent spontaneously reported
adverse event was mood lability, experienced
by 12 of the 22 children (54.5%) at some point
during the study, ranging from 13.6% to 31.8%
at individual visits over 8 weeks (Fig. 3). Spon-
taneous mood-related adverse events classified
as “mood lability” included: Angry/hostile,
brittle mood, emotionally labile, fussy, mopey,
rapid mood swings, tearful, and irritability.
Half of the children (11 of 22) experienced de-
creased appetite (ranging from 9% to 45% at in-
dividual visits over 8 weeks). Additionally, a
statistically significant mean decrease in
weight of 1.04 kg (SD 5 0.80, p , 0.001) was ob-
served for the group. Parents/guardians were
encouraged to use caloric supplementation to
limit the effect of diminished appetite, and to
give the medication after the child had eaten to
minimize stomach upset. Five year olds did not
differ significantly from 6 year olds in fre-
quency or severity of adverse events reported.
Changes in vital signs were limited; with a
mean change of systolic blood pressure of 2.98
mmHg (SD 5 5.68) the only statistically signif-
icant change (p 5 0.03) (Table 4). There were no
clinically significant changes in heart rate,
blood pressure, or on EKGs. No subjects dis-
continued due to adverse events or lack of ef-
ficacy.
DISCUSSION
The purpose of this open-label pilot study
was to evaluate the general efficacy and toler-
ability of atomoxetine in 5 and 6 year olds with
ADHD, prior to the initiation of a planned dou-
ble-blind, placebo-controlled trial in this same
population. Statistically and clinically signifi-
cant improvement in symptoms of inattention
and hyperactivity/impulsivity were observed
in this open-label study, as evidenced by 
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FIG. 1. ADHD-IV-RS. ADHD-IV-RS-Attention-Deficit/
Hyperactivity–Rating Scale-IV.
TABLE 2. CLINICAL GLOBAL IMPRESSION–SEVERITY
SCORES WERE DECREASED FROM BASELINE
TO ENDPOINT (p , 0.001)
Baseline End point
CGI-Severity n (%) n (%)
(1) Normal, not mentally ill 0 (0) 0 (0)
(2) Borderline mentally ill 0 (0) 8 (36)
(3) Mildly mentally ill 0 (0) 8 (36)
(4) Moderately mentally ill 3 (14) 3 (14)
(5) Markedly mentally ill 16 (73) 3 (14)
(6) Severely mentally ill 3 (14) 0 (0)
(7) Among the most extremely 0 (0) 0 (0)
mentally ill
CGI-S 5 Clinical Global Impression–Severity.
Overall decrease in CGI-S was statistically significant
(p , 0.001).
decreases in the total and subscale scores of 
the investigator-scored ADHD-IV-RS. An im-
provement in functional status was also ob-
served, evidenced by the changes in clinician-
rated CGAS, CGI-S, and CGI-I scores. Because
the MASC and CDI are not normed for use in
this age group, they were not used to detect
any significant changes in patient-reported
anxiety or mood symptoms. Rather these scales
were employed to support or rule out the pres-
ence of co-morbid disorders, particularly at the
baseline visit as a part of the psychiatric as-
sessment.
Atomoxetine is approved for use in children
as young as 6 years old; however, it is being
used in younger children in clinical practice.
Because children are being identified and
treated with pharmacotherapy at younger ages,
it is worthwhile to examine the efficacy and
safety of atomoxetine in a systematic fashion.
This was the first study to assess atomoxetine
use systematically in children younger than age
6 with ADHD. The authors’ interest in identi-
fication and treatment of early-childhood
ADHD, and well as their familiarity with ato-
moxetine from prior clinical trial experience,
led to this study. Inclusion of children who
were at least 5 years old allowed the investi-
gators to collect data on younger children who
were still likely to be in a structured setting
such as a school or preschool. This provided in-
vestigators with an additional reporter of
symptoms and impairment. Data obtained in
this trial and its follow-up double-blind
placebo-controlled study may lead to future
studies that extend to younger children.
Despite the majority of children reporting
at least one side effect, and at least half of the
children reporting mood lability and half re-
porting diminished appetite, the medication
was tolerated well enough so that no one dis-
continued the medication due to adverse ef-
fects. This is possibly due in part to the grad-
ual and flexible titration schedule used over the
course of treatment. There were no serious ad-
verse events during the study, and the 2 chil-
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FIG. 2. CGI-I at end point. CGI-I 5 Clinical Global Im-
pressions–Improvement.
TABLE 3. OUTCOME MEASURES COMPARING 5 YEAR OLDS TO 6 YEAR OLDS
5 year old 6 year old Wilcoxon rank sum test
p value comparing
Outcome measure n Mean (SD) n Mean (SD) age groups
Parent ADHD-IV 10 227.00 12 215.42 0.06
Total (9.19) (13.32)
Parent ADHD-IV 10 214.40 12 26.67 (7.91) 0.04
Inattentive (4.22)
Parent ADHD-IV 10 212.60 12 28.87 (7.30) 0.2
Hyperactive (6.45)
CGAS 10 22.40 12 16.00 0.2
(9.92) (13.54)
Fisher’s exact test
Count (%) Count (%) p value comparing
n improved n improved age groups
CGI-S 10 10 (100%) 12 8 (67%) 0.1
CGI-I 10 10 (100%) 12 9 (75%) 0.2
ADHD 5 Attention-Deficit/Hyperactivity Disorder Rating Scale-IV; CGAS 5 Children’s Global Assessment Scale;
CGI-I 5 Clinical Global Impression–Improvement; CGI-S 5 Clinical Global Impression–Severity; SD 5 standard de-
viation.
dren who discontinued the study after initia-
tion of treatment were those who were unable
to consistently swallow capsules. The most
commonly reported adverse events, were
mood lability (n 5 12, 54.5%) and decreased
appetite (n 5 11, 50%), with a statistically sig-
nificant decrease in weight of 1.04 kg (SD 5
0.80, p , 0.001) observed for the group. The
acute nature of the study, however, limits the
ability to assess potential long-term effects on
growth. Changes in vital signs were mild and
not clinically significant. This is congruent with
PATS, which demonstrated no significant
changes in vital signs for subjects on MPH com-
pared to those on placebo (Wigal et al. 2006).
No clinically significant changes were observed
in any of the laboratory tests or EKGs.
Mood lability was reported 1 week into treat-
ment by 7 subjects, and was present for an av-
erage of 21/2 weeks. This side effect persisted
until the end of the 8-week treatment period
for 2 of the 12 subjects. Many of the adverse ef-
fects categorized as “mood lability” have been
demonstrated in other trials of psychotropic
medications in young children. In PATS, for
example, 9 of the 14 children who discontinued
due to adverse events did so because of emo-
tionality or irritability (Greenhill et al. 2006).
Also, Safer and Zito (2006) described a review
of placebo-controlled clinical trials of seroton-
selective reuptake inhibitors (SSRIs) demon-
strating that activation was consistently more
prevalent in children than in adolescents (Safer
and Zito 2006). All of these results indicate that
younger children may be more prone to mood-
related side effects than older children and ado-
lescents. Decreased appetite appeared between
the second and fourth weeks of treatment for
the majority of the 11 subjects who reported it,
and it was an ongoing adverse event at the end
of the study for 8 subjects.
The frequency of adverse effects seen in this
study, particularly the diminished appetite and
mood lability, highlights the need for close
monitoring of young children treated with
pharmacotherapy for ADHD. Adjusting the
rate of titration, total dose given, timing of
doses, as well as caloric supplementation, can
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TABLE 4. VITAL SIGNS
Measure Baseline mean (SD) End point mean (SD) Change mean (SD)
Weight (kg) 25.0 (38.1) 23.96 (3.45) 21.04 (0.80) p , 0.001
Systolic BP (mmHg) 94.25 (4.79) 100.10 (5.15) 2.89 (5.65) p 5 0.03
Diastolic BP (mmHg) 53.55 (5.25) 55.95 (6.58) 2.41 (6.80) p 5 0.1
Pulse (bpm) 93.36 (9.66) 92.05 (15.11) 21.32 (14.37) p 5 0.9
BP 5 Blood pressure; bpm 5 beats per minute; kg 5 kilogram; mmHg 5 millimeters of mercury; SD 5 standard
deviation.
Changes from baseline to end point were not statistically or clinically significant.
FIG. 3. Adverse events N 5 22.
all potentially improve the tolerability when
difficulties are identified.
Limitations
The results of this study are limited by its
small sample size, predominantly Caucasian
male population, and open-label design.
Whereas boys constitute a higher proportion of
preschoolers with ADHD, the ratio of males to
females in this study was greater than that re-
ported in clinical preschool samples. Addition-
ally, it is difficult to identify the specific role of
the atomoxetine, because the frequency of con-
tact with the pharmacotherapist and the con-
comitant psychoeducational intervention may
have also contributed to the overall robust re-
sponse in this group. The parent education pro-
vided, while based on an evidence-based psy-
chosocial treatment (McMahon and Forehand
2003), was very abbreviated and limited to
eight 10- to 15-minute sessions (maximum of 2
hours). Parent training interventions demon-
strating efficacy in this age group are much
more intensive, averaging 8–12 hours duration,
typically with significant behavioral rehearsal,
modeling, and feedback components that the
present intervention did not include (Pister-
man et al. 1989; Strayhorn and Weidman 1989;
Sonuga-Barke et al. 2001; Bor et al. 2002). Thus,
although anecdotally many parents seemed to
find the weekly discussions about behavior
management strategies useful, it seems un-
likely that this intervention alone provided sig-
nificant direct benefits in reducing core ADHD
symptoms. Nonetheless, it is certainly possible
that the combination of psychoeducation with
pharmacotherapy provided by the same physi-
cian contributed in some indirect ways to effi-
cacy results. For example, psychoeducation
may have enhanced the physician–patient re-
lationship, which is believed to increase med-
ication compliance.
Pharmacotherapists in this study had access
to capsule strengths of atomoxetine that are not
commercially available (2.5 mg, 5 mg, 20 mg),
making smaller increases in study drug dose
during titration possible. This allowed for dos-
ing closer to the actual mg/kg dosing schedule,
and a more gradual titration not possible or
practical for clinicians in practice. Also, atom-
oxetine is only available in capsule form and
sprinkling of the capsule contents is discour-
aged. Therefore, participation in this study was
limited to those children able to swallow the ato-
moxetine capsule whole. For young children,
this may not always be possible, as evidenced
by the two discontinuations in this study. This
may be a limiting factor for clinicians in the use
of atomoxetine in younger children.
Another limitation of this study is that it only
provides data on the short-term treatment of a
disorder that generally lasts years. Longer-term
follow up with young children taking atomox-
etine to determine safety and effectiveness over
time will be important. The potential long-term
effects on growth in this population would be
of particular interest. An additional limitation
was the monitoring of adverse events by spon-
taneous report from the parent/guardian. De-
spite the high rates of adverse events, this
method of adverse event collection may have
resulted in a lower reporting rate compared to
use of a systematic collection measure.
CONCLUSIONS
This open-label study demonstrated atom-
oxetine to be effective in the treatment of 5 and
6 year olds with ADHD. Although a signifi-
cant number of children experienced adverse
events, they were often transient, and no sub-
jects discontinued due to side effects. There
were no unanticipated adverse events, al-
though the rates of decreased appetite and
mood lability were higher than expected.
Close monitoring is clearly warranted when
using atomoxetine in young children with
ADHD.
The study demonstrated the feasibility of the
diagnostic assessments and the atomoxetine
dosing strategy used, and anecdotal comments
from parents reinforced the utility of the par-
ent education protocol. These data supported
the initiation of a 120-subject randomized dou-
ble-blind placebo-controlled clinical trial cur-
rently underway at the three clinical sites.
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